[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100090910":3},{"organization":4,"armGroups":7,"interventions":15,"overallOfficials":29,"centralContacts":34,"locations":35,"responsibleParty":128,"collaborators":130,"id":134,"slug":135,"hasResults":136,"nctId":137,"briefTitle":138,"officialTitle":139,"acronym":140,"eligibilityCriteria":141,"healthyVolunteers":142,"sex":143,"minAge":144,"maxAge":34,"enrollmentInfo":145,"targetDuration":34,"studyType":148,"phases":149,"briefSummary":151,"conditions":152,"keywords":34,"overallStatus":154,"whyStopped":34,"lastUpdateSubmitDate":155,"lastUpdatePostDateStruct":156,"startDateStruct":158,"completionDateStruct":160,"leadSponsor":162,"locationsCount":163},{"fullName":5,"class":6},"Advancing Clinical Therapeutics Globally for HIV\u002FAIDS and Other Infections","NETWORK",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"EFV + FTC\u002FTDF","EXPERIMENTAL","Participants will efavirenz (600mg in pill form, taken orally, once daily) and emtricitabine\u002Ftenofovir disoproxil fumarate (200\u002F300mg in pill form, taken orally, once daily), for 48 weeks",[13,14],"Drug: Efavirenz","Drug: Emtricitabine\u002FTenofovir disoproxil fumarate",[16,23],{"type":17,"name":18,"description":19,"armGroupLabels":20,"otherNames":21},"DRUG","Efavirenz","600-mg tablet taken orally daily",[9],[22],"EFV",{"type":17,"name":24,"description":25,"armGroupLabels":26,"otherNames":27},"Emtricitabine\u002FTenofovir disoproxil fumarate","200-mg emtricitabine\u002F300-mg tenofovir disoproxil fumarate tablet taken orally once daily",[9],[28],"Truvada",[30],{"name":31,"affiliation":32,"role":33},"Mary A. Vogler, MD","Division of Infectious Diseases, Weill College of Medicine of Cornell University","STUDY_CHAIR",null,[36,49,59,69,78,87,97,108,119],{"facility":37,"status":34,"city":38,"state":39,"zip":40,"country":41,"countryCode":42,"cosmosGeoPoint":43,"geoPoint":48,"contacts":34},"Ucsd, Avrc","San Diego","California","92103","United States","US",{"type":44,"coordinates":45},"Point",[46,47],-117.16472,32.71571,{"lat":47,"lon":46},{"facility":50,"status":34,"city":51,"state":52,"zip":53,"country":41,"countryCode":42,"cosmosGeoPoint":54,"geoPoint":58,"contacts":34},"Brigham and Women's Hospital, Division of Infectious Disease","Boston","Massachusetts","02115",{"type":44,"coordinates":55},[56,57],-71.05977,42.35843,{"lat":57,"lon":56},{"facility":60,"status":34,"city":61,"state":62,"zip":63,"country":41,"countryCode":42,"cosmosGeoPoint":64,"geoPoint":68,"contacts":34},"Washington University School of Medicine","St Louis","Missouri","63108",{"type":44,"coordinates":65},[66,67],-90.19789,38.62727,{"lat":67,"lon":66},{"facility":70,"status":34,"city":71,"state":71,"zip":72,"country":41,"countryCode":42,"cosmosGeoPoint":73,"geoPoint":77,"contacts":34},"Weill Med. College of Cornell Univ., The Cornell CTU -Chelsea","New York","10011",{"type":44,"coordinates":74},[75,76],-74.00597,40.71427,{"lat":76,"lon":75},{"facility":79,"status":34,"city":80,"state":71,"zip":81,"country":41,"countryCode":42,"cosmosGeoPoint":82,"geoPoint":86,"contacts":34},"Bronx-Lebanon Hosp. Ctr. CRS","The Bronx","10457",{"type":44,"coordinates":83},[84,85],-73.86641,40.84985,{"lat":85,"lon":84},{"facility":88,"status":34,"city":89,"state":90,"zip":91,"country":41,"countryCode":42,"cosmosGeoPoint":92,"geoPoint":96,"contacts":34},"University of North Carolina","Chapel Hill","North Carolina","27514",{"type":44,"coordinates":93},[94,95],-79.05584,35.9132,{"lat":95,"lon":94},{"facility":98,"status":34,"city":99,"state":34,"zip":100,"country":101,"countryCode":102,"cosmosGeoPoint":103,"geoPoint":107,"contacts":34},"Instituto de Pesquisa Clinica Evandro Chagas Fiocruz, Fundacao Oswaldo Cruz","Rio de Janeiro","21045","Brazil","BR",{"type":44,"coordinates":104},[105,106],-43.18223,-22.90642,{"lat":106,"lon":105},{"facility":109,"status":34,"city":110,"state":111,"zip":34,"country":112,"countryCode":113,"cosmosGeoPoint":114,"geoPoint":118,"contacts":34},"San Miguel CRS","San Miguel","Lima region","Peru","PE",{"type":44,"coordinates":115},[116,117],-76.62528,-11.45222,{"lat":117,"lon":116},{"facility":120,"status":34,"city":121,"state":34,"zip":122,"country":112,"countryCode":113,"cosmosGeoPoint":123,"geoPoint":127,"contacts":34},"Barranco CRS","Lima","18",{"type":44,"coordinates":124},[125,126],-77.02824,-12.04318,{"lat":126,"lon":125},{"type":129,"investigatorFullName":34,"investigatorTitle":34,"investigatorAffiliation":34,"oldNameTitle":34,"oldOrganization":34},"SPONSOR",[131],{"name":132,"class":133},"National Institute of Allergy and Infectious Diseases (NIAID)","NIH","100090910","phase-4-hiv-treatment-reinitiation-in-women-who-received-anti-hiv-drugs-to-prevent-mother-to-child-transmission-of-hiv-100090910",true,"NCT00442962","HIV Treatment Reinitiation in Women Who Received Anti-HIV Drugs to Prevent Mother-to-Child Transmission of HIV","The Effect of Prior Short Course Combination Antiretroviral Therapy Administered for the Prevention of Mother-to-Child Transmission (pMTCT) of HIV-1 on Subsequent Treatment Efficacy in Treatment-\"Nearly Naive\" Participants","Nearly Naive","Inclusion Criteria:\n\n* HIV-1 infected\n* Viral load of 500 copies\u002FmL or more\n* Prior HAART for more than 7 days, but less than 40 weeks during at least one previous pregnancy for prevention of MTCT of HIV\n* Clinical or laboratory indication to start HAART, in the opinion of the participant's physician\n* Certain laboratory values\n* Willingness to use acceptable forms of contraception\n* Parent or guardian willing to provide informed consent, if applicable\n\nExclusion Criteria:\n\n* Taking any antiretroviral medication within 24 weeks prior to study entry\n* Evidence of certain HIV-1 RT mutations within 90 days prior to study entry (version 1.0)\n* Evidence of certain HIV-1 RT mutations identified by standard bulk viral population genotypic resistance tests at any time prior to study entry, if available (version 2.0, 09\u002F03\u002F2009)\n* Treatment at any time, for any reason with nevirapine as a single agent OR addition of any part of the study regimen as a single agent to a failing regimen\n* Use of certain antihistamines, certain anti-infectives, cisapride, St John's wort, midazolam, triazolam, dihydroergotamine, ergonovine, ergotamine, or methylergonovine within 14 days prior to study entry\n* Use of HIV vaccine, chronic systemic corticosteroids, interleukins, interferons, other cytokines, or investigational therapy within 30 days prior to study entry\n* Acute or chronic therapy for certain serious medical illnesses within 14 days of study entry. Participants who have completed 7 days of therapy and are judged clinically stable are not excluded.\n* Cancer requiring systemic chemotherapy\n* Known allergy\u002Fsensitivity to the study drugs or their formulations\n* Current drug or alcohol use that, in the opinion of the investigator, would interfere with the study\n* Two consecutive HIV viral loads of more than 5,000 copies\u002FmL 8 weeks or more following initiation of HAART during pregnancy and while still receiving HAART\n* Two consecutive viral loads of more than 400 copies\u002FmL 24 weeks or more following initiation of HAART during pregnancy while still receiving HAART\n* Current imprisonment or involuntary incarceration in a medical facility for psychiatric or physical illness\n* Pregnancy or breastfeeding",false,"FEMALE","16 Years",{"count":146,"type":147},54,"ACTUAL","INTERVENTIONAL",[150],"PHASE4","The purpose of this study is to determine if pregnancy-limited, short-term combination HIV treatment regimens -- which were used solely for the prevention of mother to child transmission of HIV and discontinued postpartum -- decreases the effectiveness of a standard initial regimen of anti-HIV drugs when subsequent treatment is needed.",[153],"HIV Infections","COMPLETED","2018-09-11",{"date":157,"type":147},"2018-10-12",{"date":159,"type":34},"2007-05",{"date":161,"type":147},"2010-12",{"name":5,"class":6},9]